Cargando…
Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers
BACKGROUND: Additional accurate non-invasive biomarkers are needed in the clinical setting to improve prostate cancer (PCa) diagnosis. Here we have developed a new and improved multiplex mRNA urine test to detect prostate cancer (PCa). Furthermore, we have validated the PCA3 urinary transcript and s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746764/ https://www.ncbi.nlm.nih.gov/pubmed/26856686 http://dx.doi.org/10.1186/s12885-016-2127-2 |
_version_ | 1782414858929569792 |
---|---|
author | Mengual, Lourdes Lozano, Juan José Ingelmo-Torres, Mercedes Izquierdo, Laura Musquera, Mireia Ribal, María José Alcaraz, Antonio |
author_facet | Mengual, Lourdes Lozano, Juan José Ingelmo-Torres, Mercedes Izquierdo, Laura Musquera, Mireia Ribal, María José Alcaraz, Antonio |
author_sort | Mengual, Lourdes |
collection | PubMed |
description | BACKGROUND: Additional accurate non-invasive biomarkers are needed in the clinical setting to improve prostate cancer (PCa) diagnosis. Here we have developed a new and improved multiplex mRNA urine test to detect prostate cancer (PCa). Furthermore, we have validated the PCA3 urinary transcript and some panels of urinary transcripts previously reported as useful diagnostic biomarkers for PCa in our cohort. METHODS: Post-prostatic massage urine samples were prospectively collected from PCa patients and controls. Expression levels of 42 target genes selected from our previous studies and from the literature were studied in 224 post-prostatic massage urine sediments by quantitative PCR. Univariate logistic regression was used to identify individual PCa predictors. A variable selection method was used to develop a multiplex biomarker model. Discrimination was measured by ROC curve AUC for both, our model and the previously published biomarkers. RESULTS: Seven of the 42 genes evaluated (PCA3, ELF3, HIST1H2BG, MYO6, GALNT3, PHF12 and GDF15) were found to be independent predictors for discriminating patients with PCa from controls. We developed a four-gene expression signature (HIST1H2BG, SPP1, ELF3 and PCA3) with a sensitivity of 77 % and a specificity of 67 % (AUC = 0.763) for discriminating between tumor and control urines. The accuracy of PCA3 and previously reported panels of biomarkers is roughly maintained in our cohort. CONCLUSIONS: Our four-gene expression signature outperforms PCA3 as well as previously reported panels of biomarkers to predict PCa risk. This study suggests that a urinary biomarker panel could improve PCa detection. However, the accuracy of the panels of urinary transcripts developed to date, including our signature, is not high enough to warrant using them routinely in a clinical setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2127-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4746764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47467642016-02-10 Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers Mengual, Lourdes Lozano, Juan José Ingelmo-Torres, Mercedes Izquierdo, Laura Musquera, Mireia Ribal, María José Alcaraz, Antonio BMC Cancer Research Article BACKGROUND: Additional accurate non-invasive biomarkers are needed in the clinical setting to improve prostate cancer (PCa) diagnosis. Here we have developed a new and improved multiplex mRNA urine test to detect prostate cancer (PCa). Furthermore, we have validated the PCA3 urinary transcript and some panels of urinary transcripts previously reported as useful diagnostic biomarkers for PCa in our cohort. METHODS: Post-prostatic massage urine samples were prospectively collected from PCa patients and controls. Expression levels of 42 target genes selected from our previous studies and from the literature were studied in 224 post-prostatic massage urine sediments by quantitative PCR. Univariate logistic regression was used to identify individual PCa predictors. A variable selection method was used to develop a multiplex biomarker model. Discrimination was measured by ROC curve AUC for both, our model and the previously published biomarkers. RESULTS: Seven of the 42 genes evaluated (PCA3, ELF3, HIST1H2BG, MYO6, GALNT3, PHF12 and GDF15) were found to be independent predictors for discriminating patients with PCa from controls. We developed a four-gene expression signature (HIST1H2BG, SPP1, ELF3 and PCA3) with a sensitivity of 77 % and a specificity of 67 % (AUC = 0.763) for discriminating between tumor and control urines. The accuracy of PCA3 and previously reported panels of biomarkers is roughly maintained in our cohort. CONCLUSIONS: Our four-gene expression signature outperforms PCA3 as well as previously reported panels of biomarkers to predict PCa risk. This study suggests that a urinary biomarker panel could improve PCa detection. However, the accuracy of the panels of urinary transcripts developed to date, including our signature, is not high enough to warrant using them routinely in a clinical setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2127-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-02-09 /pmc/articles/PMC4746764/ /pubmed/26856686 http://dx.doi.org/10.1186/s12885-016-2127-2 Text en © Mengual et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Mengual, Lourdes Lozano, Juan José Ingelmo-Torres, Mercedes Izquierdo, Laura Musquera, Mireia Ribal, María José Alcaraz, Antonio Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers |
title | Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers |
title_full | Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers |
title_fullStr | Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers |
title_full_unstemmed | Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers |
title_short | Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers |
title_sort | using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mrna urine test and validation of current biomarkers |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746764/ https://www.ncbi.nlm.nih.gov/pubmed/26856686 http://dx.doi.org/10.1186/s12885-016-2127-2 |
work_keys_str_mv | AT menguallourdes usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers AT lozanojuanjose usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers AT ingelmotorresmercedes usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers AT izquierdolaura usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers AT musqueramireia usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers AT ribalmariajose usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers AT alcarazantonio usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers |